BioSpace News Archive

Prevail Therapeutics Inc., a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, announced that the U.S. Food and Drug Administration has granted Fast Track designation for the Company’s experimental gene therapy program, PR001, for the treatment of neuronopathic Gaucher disease.

Alzheimer’s disease affects more than 5.8 million Americans at an estimated cost at over $305 billion in 2020 according to the Alzheimer’s Association.

Avanos Medical, Inc. will webcast its conference call discussing financial results and business highlights for the third quarter 2020 on Tuesday, Nov. 3 at 9 a.m. ET.

Expression data suggest potential of PVRIG inhibition to enhance T cell priming and infiltration into both inflamed and less inflamed tumors

Brings Together Cancer Screening R&D Pioneers to Transform the Future of Cancer Diagnostics and Impact Lives

Lodo’s Informatics-Enabled Drug Discovery Platform Accesses the Vast Collections of Undiscovered Drug-Like Molecules Encoded in Microbial DNA

Zolgensma is the first gene therapy based on REGENXBIO’s NAV® Technology Platform approved by the FDA and other regulatory authorities

Acorda Therapeutics, Inc. will host a conference call and webcast in conjunction with its third quarter 2020 update and financial results on Tuesday, November 3 at 4:30 p.m. ET.

NeoGenomics, Inc., a leading provider of cancer-focused genetics testing services, announced its third-quarter results for the period ended September 30, 2020.

Submission based on the CheckMate -9ER phase 3 pivotal trial, which showed CABOMETYX in combination with OPDIVO improved overall survival and doubled median progression-free survival and objective response rate versus sunitinib